Gaucher's disease in children: First clinical signs, natural course and benefits of enzyme replacement therapy;La maladie de Gaucher chez l'enfant: Mode de révélation, évolution naturelle, apports du traitement par l'enzyme de remplacement

Archives de Pediatrie

Volumn 10, Issue 8, 2003, Pages 681-688

  Caubel, I ^a   Billette de Villemeur, T ^a   Belmatoug, N ^b   Saudubray, J M ^c   Baumann, N ^c   Broissand, C ^c   Caillaud, C ^c   Carbon, C ^c   Guffon, N ^c   Guibaud, P ^c   Guillard, J M ^c   Herbrecht, R ^c   Kaminski, P ^c   Maire, I ^c   Ponsot, G ^c   Poenaru, L ^c   Schaison, G ^c   Taksin, L ^c   Vanier, M T ^c   Vidailhet, M ^c   Youssov, K ^c   more..

^a ARMAND TROUSSEAU HOSPITAL   (France)

^b BEAUJON HOSPITAL   (France)

^c NONE

Author keywords

Child; Enzymes, therapeutic use; Gaucher's disease; Lysosomal storage diseases

Indexed keywords

ALGLUCERASE; IMIGLUCERASE;

ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; DISEASE SEVERITY; ENZYME REPLACEMENT; FOLLOW UP; GAUCHER DISEASE; HUMAN; SCORING SYSTEM; TREATMENT OUTCOME;

EID: 0041513470     PISSN: 0929693X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0929-693X(03)00286-0     Document Type: Article

References (27)

1. Gaucher PCE. De l'épithelioma primitif de la rate: hypertrophie idiopathique de la rate sans leucémie [thèse]. Paris: faculté de médecine; 1882.
2. Grabowski GA, Horowitz M. Gaucher's disease: molecular, genetic and enzymological aspects. Baillieres Clin Haematol 1997;10:635-56.
3. Kolodny EH, Ullman MD, Mankin HJ, Raghavan SS, Topol J, Sullivan JL. Phenotypic manifestations of Gaucher disease: clinical features in 48 biochemically verified type 1 patients and comment on type 2 patients. Prog Clin Biol Res 1982;95:33-65.
4. Stirnemann J, Belmatoug N. La maladie de Gaucher chez l'adulte. Rev Méd Interne 2001;22(Suppl 3):374s-83s.
5. Germain DP, Puech JP, Caillaud C, Kahn A, Poenaru L. Exhaustive screening of the acid β-glucosidase gene by fluorescence-assisted mismatch analysis using universal primers: mutation profile and genotype-phenotype correlations in Gaucher disease. Am J Hum Genet 1998;63:415-27.
6. Zimran A, Sorje J, Gross E, Kubitz M, West C, Beutler E. Prediction of severity of Gaucher's disease by identification of mutations at DNA level. Lancet 1989;2:349-52.
7. Mistry PK, Abrahamov A. A practical approach to diagnosis and management of Gaucher's disease. Baillieres Clin Haematol 1997;10: 817-38.
8. Aetrs JM, Hollak CE. Plasma and metabolic abnormalities in Gaucher's disease. Baillieres Clin Haematol 1997;10:691-709.
9. Billette de Villemeur T. Maladie de Gaucher. Les maladies lysosomales, 4. Evry: Association vaincre les maladies lysosomales (éd); 1994. p. 12-5.
10. Brady RO. The Sphingolipidoses. N Engl J Med 1966;275:312-8.
11. Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, et al. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Lancet 1994;344:1679-82.
12. Grabowski GA, Leslie N, Wenstrup R. Enzyme therapy for Gaucher's disease: the first 5 years. Blood Rev 1998;12:115-33.
13. Niederau C, vom Dahl S, Haussinger D. First long-term results of imiglucerase therapy of type 1 Gaucher disease. Eur J Med Res 1998;3:25-30.
14. Erikson A, Johansson K, Mänsson JE, Svennerholm L. Enzyme replacement therapy of infantile Gaucher's diasease. Neuropediatrics 1993;24:237-8.
15. Prows CA, Sanchez N, Daugherty C, Grabowski GA. Gaucher's disease: enzyme therapy in the acute neuronopathic variant. Am J Med Genet 1997;71:16-21.
16. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, Pastores G, et al. The Gaucher's registry: demographics and disease characteristics of 1698 patients with Gaucher's disease. Arch Intern Med 2000;160:2835-43.
17. Haddad-Zebouni S, Hindy R, Slaba S, Aoun N, Mourani C, Abi Ghanem S, et al. Ultrasonographic evaluation of the kidney, liver and spleen size in children. Arch Pédiatr 1999;6:1266-70.
18. Bilchik TR, Heyman S. Skeletal scintigraphy of pseudo-osteomyelitis in Gaucher's disease. Two case reports and a review of the literature. Clin Nucl Med 1992;17:279-82.
19. Zevin S, Abrahamov A, Hadas-Halpem I, Kannai R, Levy-Lahad E, Horowitz M, et al. Adult-type Gaucher's disease in children: genetics, clinical features and enzyme replacement therapy. Q J Med 1993;86: 565-73.
20. Beutler E, Demina A, Laubscher K, Garver P, Gelbart T, Balicki D, et al. The clinical course of treated and untreated Gaucher's disease. A study of 45 patients. Blood Cells Mol Dis 1995;21:86-108.
21. Sidransky E, Tayebi N, Ginns EI. Diagnosing Gaucher's disease: early recognition, implications for treatment and genetic counseling. Clin Pediatr (Phila) 1995;34:365-71.
22. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, et al. Acceleration of retarded growth in children with Gaucher's disease after treatment with alglucerase. J Pediatr 1996;129:149-53.
23. James SP, Stromeyer FW, Stowens DW, Barranger JA. Gaucher's Disease: hepatic abnormalities in 25 patients. Prog Clin Biol Res 1982;95:131-42.
24. Allison JW, James CA, Arnold GL, Stine KC, Becton DL, Bell JM. Reconversion of bone marrow in Gaucher's disease treated with enzyme therapy documented by MR. Pediatr Radiol 1998;28:237-40.
25. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, McKusick KA, et al. Enzyme replacement therapy for Gaucher's disease: skeletal response to macrophage-targeted glucocerebrosidase. Pediatrics 1995;96:629-37.
26. Schiffmann R, Heyes MP, Aerts JM, Dambrosia JM, Patterson MC, DeGraba T, et al. Prospective study of neurological responses to treatment with macrophage-targeted glucocerebrosidase in patients with type 3 Gaucher's disease. Ann Neurol 1997;42:613-21.
27. Altarescu G, Hill S, Wiggs E, Jeffries N, Kreps C, Parker CC, et al. The efficacy of enzyme replacement therapy in patients with chronic neuronopathic Gaucher's disease. J Pediatr 2001;138:539-47.